Welcome to our dedicated page for Adma Biologics SEC filings (Ticker: ADMA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Looking for the line that explains how many liters of high-titer plasma ADMA Biologics turns into specialty immunoglobulin each quarter? Start your research here. Our SEC dashboard pulls every filing—10-K annual reports, 10-Q quarterly earnings updates, Form 4 insider trading notices, 8-K material events—within minutes of hitting EDGAR, so you never miss an FDA update or production metric.
Use Stock Titan’s AI to skim a 250-page report in seconds. The platform highlights where management discusses manufacturing capacity, cash runway, and regulatory milestones, turning understanding ADMA Biologics SEC documents with AI into a two-click task. Need the latest ADMA Biologics quarterly earnings report 10-Q filing? It’s tagged and summarized, complete with segment revenue trends and yield-per-liter calculations. Tracking ownership shifts? Real-time alerts flag every ADMA Biologics Form 4 insider transactions so you can gauge executive confidence before news breaks.
Whether you’re comparing R&D spend across periods, monitoring an 8-K announcing new FDA correspondence, or dissecting the ADMA Biologics proxy statement executive compensation tables, our coverage is exhaustive and our explanations clear. Investors routinely watch ADMA Biologics insider trading Form 4 transactions for cues around trial read-outs, and analyze the ADMA Biologics annual report 10-K simplified to understand long-term supply-chain strategy. Stop wading through dense biotech jargon; let AI surface the insights that shape informed decisions.
Adam S. Grossman, President and CEO and a director of ADMA Biologics, reported multiple transactions on 08/15/2025 under a Rule 10b5-1 plan. He exercised an option covering 15,000 shares with an exercise/conversion price of $5.40 and simultaneously sold 21,000 shares (15,000 and 6,000) at $16.88 per share. Following these transactions the reporting person directly beneficially owns 2,031,850 shares. He also has indirect interests of 1,143,426 shares through Areth, LLC and 580,957 shares through Hariden, LLC. Footnotes disclose large unvested RSU balances totaling 1,033,166 shares across multiple grants and an outstanding option schedule tied to a 2024 grant.
State Street Corporation reported beneficial ownership of 12,078,505 shares of ADMA Biologics common stock, equal to 5.1% of the outstanding class. The filing discloses shared voting power over 11,187,440 shares and shared dispositive power over 12,078,505 shares, while reporting no sole voting or sole dispositive power. The holder states the position is maintained in the ordinary course of business and not held to influence control of the issuer. Several State Street affiliates are identified as the acquiring subsidiaries and are classified as investment advisers.
ADMA Biologics (ADMA) Form 4 highlights: Chief Operating Officer & SVP Compliance Kaitlin M. Kestenberg-Messina exercised 2,500 employee stock options on 07/30/2025 at an exercise price of $8.98 (code “M”).
To satisfy the exercise price and mandatory tax withholding, 1,208 shares were withheld by the issuer (code “F”), so no open-market sale occurred. Net 1,292 shares were added to the insider’s direct holdings.
Post-transaction ownership: 488,690 directly held common shares, consisting of 194,166 fully vested shares and 294,524 unvested RSUs from grants made between 2022-2025 that will vest quarterly over four-year schedules.
The 07/30/2015 option grant is now fully exercised and no derivative securities from this grant remain outstanding.
No other transactions, purchases, or sales were reported. Filing was signed 08/01/2025.
ADMA Biologics COO & SVP, Compliance Kaitlin M. Kestenberg-Messina filed a Form 4 for an automatic share withholding event on 07/24/2025. Transaction code F shows 3,027 common shares were surrendered to the company at $17.31 per share to satisfy payroll-tax obligations triggered by the vesting of restricted stock units (RSUs); no shares were sold on the open market.
Post-transaction, the executive beneficially owns 487,398 ADMA shares, comprised of 192,874 fully vested shares and 294,524 unvested RSUs that vest quarterly through 2029, contingent on continued service.
- The filing is a routine tax-settlement and does not reflect a discretionary reduction in ownership.
- Share count outstanding is modestly reduced, but insider economic exposure is unchanged.
ADMA Biologics (ADMA) Form 4 filing: CFO & Treasurer Brad L. Tade reported an automatic disposition of 7,123 common shares on 07/24/2025 using transaction code “F”, which indicates shares were withheld by the issuer solely to satisfy payroll-tax obligations triggered by restricted-stock-unit (RSU) vesting. The shares were valued at $17.31, an implied $123 k transaction value.
Following the tax withholding, Tade directly owns 239,419 shares. This total includes about 204,027 unvested RSUs granted in 2023-2025 that vest quarterly over four-year periods, plus 35,392 previously acquired shares. No derivative securities were bought or sold, and no open-market activity occurred.
The filing is routine, involves no cash proceeds to the insider, does not alter the company’s share count, and has limited market impact.
Form 4 overview: ADMA Biologics (ticker ADMA) disclosed that Chief Financial Officer & Treasurer Brad L. Tade had 9,838 common shares withheld on 06/26/2025 (transaction code “F”). The “F” code means the shares were automatically surrendered to the company to satisfy statutory tax-withholding obligations triggered by the vesting of previously granted restricted stock units (RSUs); it was not an open-market sale.
Post-transaction holdings: Tade’s stated beneficial ownership is 246,542 shares after the withholding event. This figure comprises:
- 186,127 unvested RSUs spread across four grant dates (June 2023, Feb 2024, July 2024, Feb 2025) that vest quarterly over four years, contingent on continued employment.
- 24,415 fully vested shares accumulated through open-market purchases and past RSU settlements.
- The remaining balance represents fully vested shares already held.
No derivative activity was reported in Table II, and there were no purchases or sales of stock options or other instruments.
Investor takeaway: The filing is routine and signals mandatory tax withholding rather than discretionary selling. Insider equity alignment remains intact; the CFO continues to hold a meaningful stake that will grow as RSUs vest.
FAQ
What is the current stock price of Adma Biologics (ADMA)?
What is the market cap of Adma Biologics (ADMA)?
